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Abstract The aim of the study was to determine the prev-
alence and genotypes of HPV infection in laryngeal cancer
specimens, normal mucosa obtained from the surgical mar-
gin and laryngeal nodules using a novel high sensitive and
speciWc SPF10 HPV DNA test, PCR/DEIA method and
INNO-LiPA genotyping assay. The correlation between
HPV presence and clinico-pathological features was ana-
lyzed. Tissue samples were collected from 93 primary laryn-
geal squamous cell carcinoma (LSCC), 49 specimens of
normal mucosa and from 22 specimens of laryngeal nodules
serving as control group. HPV DNA was ampliWed by the
short PCR fragment (SPF10) primer set using HPV DNA
enzyme immunoassay (DNA/DEIA) method and INNO-
LiPA HPV genotyping assay. Human papillomavirus was
detected in 33 (35.5%) of the 93 samples from LSCC, in 4
(8.2%) of 49 samples of the normal mucosa and it was not
detected in any of the sample from the control group.
Twenty-eight of 33 (81.8%) were positive for HPV-16, 6 of
33 (18.2%) were positive for HPV-18 and 5 of 33 (15.1%)
were positive for HPV-33. Multiple infection was found in 5
of 33 (15.1%); 3 samples were positive for HPV-16 and
HPV-33, 2 samples for HPV-16 and HPV-18. There was a
statistically signiWcant correlation between the presence of
HPV in LSCC tumors and in control group samples and
between the presence of HPV in the tumors and normal
mucosa from the free surgical margin. The presence of HPV
infection in 35.5% of the cases suggests a possible role in
the etiology of laryngeal cancer and supports the role of
high-risk types of HPV (16, 18 and 33) in LSCC. HPV
infection is not likely to inXuence survival rates as an inde-
pendent prognostic factor in patients with laryngeal cancer.
Keywords HPV · Laryngeal cancer · Normal mucosa · 
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Introduction
The larynx is the most common site of malignancy in the
upper aerodigestive tract and the laryngeal squamous cell
carcinoma (LSCC) is the histology of the tumor in over
than 90% of cases. The etiology of LSCC is considered to
be multifactorial. The main predisposing factors are
tobacco and alcohol use [1]. Human papillomavirus (HPV)
infections, nutritional deWciency and local dietary customs
have also been implicated in the etiology of laryngeal can-
cer [1–3].
Human papillomaviruses (HPVs) are small double-
stranded DNA viruses that induce hyperproliferative lesions
of cutaneous and mucosal epithelia. Papillomaviruses can be
divided into low-risk types, which induce only benign
lesions, and high-risk types, which are associated with the
development of malignant lesions [4]. More than 90% of
cervical cancers contain HPV DNA of the high-risk types [5,
6]. The two transforming proteins encoded by the high-risk
HPVs, E6 and E7, function through their associations with
the tumor suppressor proteins p53 and Rb [7]. One hundred
and eighteen papillomavirus (PV) types have been com-
pletely described and approximately 120 additional isolates
represent only partially characterized putative novel geno-
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types [5]. Particularly, HPV-16 is suspected to play a role in
etiopathogenesis of LSCC [1,  2]. The diagnosis of HPV
infection is almost entirely based on molecular tools, which
are mainly PCR-based. General or consensus PCR primers
have been developed that detect a broad spectrum of HPV
genotypes in a single PCR [7–9]. Several techniques have
been used to detect the presence of HPV in tissues. In LSCC
a novel, high sensitive and broad-spectrum SPF10 PCR/
DEIA method has been poorly investigated so far. The
SPF10 PCR/DEIA method has been established and investi-
gated in the cervical squamous cell carcinoma [8, 9].
The aim of the study was to determine the prevalence
and genotypes of HPV infection in laryngeal cancer speci-
mens, normal mucosa obtained from the surgical margin
and laryngeal nodules using a novel high sensitive and spe-
ciWc SPF10 HPV DNA test and PCR/DEIA method. The
correlation between the presence of HPV and clinico-path-
ological features was analyzed.
Materials and methods
Tissue specimens were obtained from 93 consecutive
patients with primary LSCC operated upon by the Wrst
author in the Department of Otolaryngology Head and
Neck Surgery, Medical University of Lublin in the years
1999–2002. The group consisted of 78 males and 15
females, aged between 32 and 78 years (mean 57.7 years).
The specimens were collected during a primary diagnostic
microlaryngoscopy. Patients were treated surgically with or
without postoperative radiotherapy depending of the clini-
cal stage of the disease. The patients had neither previous
radiotherapy nor chemotherapy. TNM classiWcation was
according to the Union Against Cancer (UICC) criteria.
Histologic grading was performed according to the World
Health Organization criteria, which divides the tumor into
well diVerentiated (G1), moderately well diVerentiated
(G2), and poorly diVerentiated (G3) types.
Tissue samples from the normal mucosa from the surgical
margin were collected from 49 patients with LSCC. After
that, total laryngectomy samples of the normal mucosa from
the surgical margin, 1–2 cm from the palpated or visible
tumor, were obtained. Special care was taken not to contami-
nate the samples. Single use and sterile instruments were
used to harvest and store the samples. The lymph-node
metastases were not tested for HPV presence. Non-neoplastic
laryngeal lesions -laryngeal nodules served as control group.
The tissue specimens were harvested from 22 patients, 12
males and 10 females aged between 21 and 71 years (mean
41.4 years) operated in our institution and the histological
evaluation conWrmed the diagnosis in all cases.
The clinicopathological features of the patients with
LSCC are shown in Table 1.
The study project was approved by the Local Institu-
tional Review Board.
DNA extraction from paraYn sections
Five, 10-m sections of formalin-Wxed, paraYn-embedded tis-
sue were transferred to eppendorf vials after cutting deep into
the block. The microtome blade was changed after each case.
DNA extraction from tissue specimens was done using stan-
dardization Genomic Mini test for DNA extraction kit (Geno-
mic DNA Prep Plus A&A Biotechnology Gdynia, Poland).
After deparaVinization, tissue sample was transferred to fresh
eppendorf viols and incubated at 50°C with 100 l Tris buVer,
50 l universal lyses solution LT and 20 l proteinase K, and
was rotated for the complete digesting of the tissue sample.
After incubation, 150 l LT buVer were added and it was cen-
trifuged for 3 min. at 10,000–15,000 rpm and washed twice
with 98% ethanol. The precipitated DNA was centrifuged for
1 min at 10,000–15,000 rpm and again washed with 70% eth-
anol. The DNA was precipitated and dried. The dried DNA
extracts were incubated for 5 min at room temperature with
200 l Tris buVer (10 mM Tris–HCl pH 8.5), which had a
75°C temperature and then it was centrifuged for 1 min at
10,000–15,000 rpm. The obtained DNA extracts was stored at
¡25°C for further analysis.
-globin ampliWcation
To analyze the DNA quality PCR ampliWcation of -globin
was performed in a separate reaction using primers PC04
and KM29 with fragment of 205 bp. The sequence of the
set primer of PCO4 was d(5-CAA CTT CAT CCA CGT
TCA CC-3) and for KM29 was d(5-GGT TGG CCA ATC
TAC TCC CAG G-3).
HPV DNA detection
Human papillomavirus DNA was ampliWed by the short
PCR fragment (SPF10) HPV primer set (Labo Bio-medical
Products B.V., Holland). The SPF10 primers amplify a 65-
bp fragment from the L1 region of the HPV genome as
described by Kleter et al. [8]. The PCR products were ana-
lyzed by both 3% agarose gel electrophoresis and HPV
DNA enzyme immunoassay (DNA/DEIA). Each run was
accompanied by quality control samples. During each PCR
run, samples were tested, together with one negative con-
trol (distilled H2O) and one positive control (Caski culture
cell line). AmpliWcation products were tested by probe
hybridization in a microtiter plate assay to detect the pres-
ence of HPV DNA as described earlier by Kleter et al. [8]
This assay also included appropriate negative and positive
controls. Amplicons from HPV-positive samples were ana-
lyzed using the INNO-LiPA HPV genotyping assay, whichEur Arch Otorhinolaryngol (2008) 265 (Suppl 1):S89–S96 S91
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permits speciWc detection of 25 HPV genotypes (HPV
types 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52,
53, 54, 56, 58, 59, 66, 68, 70, 73 and 74). The assay has
been described in detail earlier [8, 9].
Control samples
DNA from the Caski cell line was used as a positive PCR
control to assess the success of the ampliWcation. PCR
reagents lacking DNA (Distilled H2O) served in each PCR
ampliWcation as a negative control. The detection of DNA
of necessary quality was performed by -globin assay.
Statistical analysis
Statistical analysis was performed to investigate the rela-
tionship between HPV presence and clinico-pathological
and demographical parameters by means of the 2 test





N = 60 (64.5%)
HPV-positive 
N = 33 (35.5%)
Statistical signiWcance
No. % No. %
Sex
Men 78 51 65.4 27 34.6 2 = 0.16; P =0 . 6 9
Women 15 9 60 6 40
Age (years)
·60 58 35 60.3 23 39.7 2 = 1.17; P =0 . 2 8
> 60 35 25 71.4 10 20.6
Alcohol abuse
Yes 68 45 66.2 23 33.8 2 = 0.69; P =0 . 4 1
No 23 13 56.5 10 43.5
Smoking
Yes 80 54 67.5 26 32.5 2 =0 . 5 ;   P =0 . 4 8
No 11 7 63.6 4 36.4
Localization
Supraglottic 54 34 63 20 37 2 = 0.27; P = 0.87 
Supraglottic versus glottic 
2 = 0.07; P =0 . 7 9
Glottic 35 23 65.7 12 34.3
Subglottic 4 3 75 1 25
T stage
T1 9 7 77.7 2 22.2 2 = 1.83; P = 0.61 
T1+2 versus 
T3+4 2 = 0.88; P =0 . 3 5
T2 10 7 70 3 30
T3 40 23 57.5 17 42.5
T4 34 23 67.7 11 32.3
N stage
N0 49 34 69.4 15 30.6 2 = 4,37; P = 0,22 
N0 versus N1+2+3 
2 = 1.07; P =0 . 3
N1 28 15 53.6 13 46.4
N2 12 7 58.3 5 41.7
N3 4 4 0 0 0
Clinical stage
I stage 9 7 77.8 2 22.2 2 = 1.32; P = 0.72 
clinical stage I + II versus III + IV 
2 = 0.74; P =0 . 3 9
II stage 8 6 75 2 25
III stage 24 15 62.5 9 37.5
IV stage 52 32 61.5 20 38.5
Histology grade
G1 26 18 69.2 8 30.8 2 = 0.59; P =0 . 7 5
G2 53 34 64.2 19 35.8
G3 14 8 57.1 6 42.9S92 Eur Arch Otorhinolaryngol (2008) 265 (Suppl 1):S89–S96
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(2 £ 2 table and contingence table). Survival rates at 3 and
5-year follow-up for overall survival (OS) and disease-
speciWc survival (DSS) were calculated using the method of
Kaplan–Meier and the diVerences between curves were
assessed with the log-rank test. Cox’s regression model was
used to evaluate the predictive power of various factors in
multivariate analysis. Statistical signiWcance was deWned as
P <0 . 0 5 .
Results
The -globin DNA was ampliWed in 93 samples with LSCC
(Fig. 1), in 49 samples of normal mucosa from the larynx
and in 22 patients with laryngeal nodules indicating the
presence of ampliWable DNA in all cases.
Using the SPF10 set primer HPV was detected in 33
(35.5%) of the 93 samples from LSCC (Fig. 2), in 4 (8.2%)
of 49 samples of the normal mucosa from the surgical mar-
gin in patients with LSCC and it was not detected in any of
the sample from the control group. In patients with the
HPV-positive samples in the normal mucosa from the sur-
gical margin, the tumor samples were also HPV positive.
Among the HPV-positive samples from LSCC, 28 of 33
(81.8%) were positive for HPV-16, 6 of 33 (18.2%) were
positive for HPV-18 and 5 of 33 (15.1%) were positive for
HPV-33. Multiple infection was found in 5 of 33 (15.1%);
3 samples were positive for HPV-16 and HPV-33, 2 sam-
ples for HPV-16 and HPV-18. Among the HPV-positive
samples from normal mucosa from the surgical margin in
patients with LSCC all four samples were positive for
HPV-16.
The diVerence between the presence of HPV in squa-
mous cell carcinoma tumors and in control group samples
was statistically signiWcant (2 =8 . 1 3 ;  P = 0.004). The
diVerence between the presence of HPV in squamous cell
carcinoma tumors and in normal mucosa from the surgical
margin in patients with LSCC samples was statistically sig-
niWcant (2 =3 . 7 8 ;   P = 0.05).
The demographical and clinicopathological features of
HPV positive patients are shown in Table 1. Twenty-seven
males and 6 females were HPV positive. Eight (24.2%) of
33 samples with HPV positive tumors were classiWed as
G1, 19 (57.6%) were G2 and 6 (18.2%) were G3. Twenty
(60.6%) of the 33 HPV positive tumors were supraglottic,
12 (36.4%) were located in glottis and one (3%) in subglot-
tic region. Twenty-eight (84.4%) of the 33 HPV positive
tumors were T3 or T4 and 5 (15.6%)were T1 or T2. Fifteen
(45.5%) of 33 HPV positive patients had no clinically evi-
dent cervical lymph nodes (N0) and 18 (54.5%) of HPV
positive patients had lymph node involvement (N1 or N2).
Twenty-six HPV-positive patients were heavy cigarette
smokers and 23 of 33 frequently consumed alcohol. No sig-
niWcant correlation was found between HPV incidence and
epidemiological factors or histological grade or clinical
stage of tumor.
Two males and two females were HPV positive. Three
of the four HPV-positive tumors were supraglottic and one
(25%) was located in glottis. In all of the patients with
HPV-positive normal mucosa the tumors were in the
advanced stage (T3 or T4). One of the four patients with
HPV-positive normal mucosa had no clinically evident cer-
vical lymph nodes (N0) and three patients with HPV-posi-
tive normal mucosa had evident lymph-node involvement.
In three of four patients with HPV-positive normal mucosa,
tumors were G3 and in 1 sample the tumor was G1 (well
diVerentiated).
Fig. 1 Agarose gel electrophoresis of the PCR products of -globin
ampliWcation specimens. Lane M molecular weight marker, lane 10
negative control for -globin, lanes 1, 2, 3, 4, 5, 7, 8, 9 -globin posi-
tive specimens, lane 6 -globin negative specimen 
1   2  3       4        5       M     6     7    8        9      10 
205 pb 
M – Molecular weight marker
10 – Negative control for β-globin
1, 2, 3, 4, 5, 7, 8, 9 – β-globin positive specimens  
6 – β-globin negative specimen
 
Fig. 2 Agarose gel electrophoresis of the PCR/DEIA products of
HPV DNA detection. Lane M molecular weight, marker, lane 1 posi-
tive control, lanes 3, 4, 5, 6 HPV positive specimens, lane 2 HPV neg-
ative specimen
1              2              3             4               5            6             M
65 pb 
M – Molecular weight marker
1 – Positive control
3, 4, 5, 6 – HPV positive specimens
2 – HPV negative specimenEur Arch Otorhinolaryngol (2008) 265 (Suppl 1):S89–S96 S93
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Survival and recurrence analysis
It was possible to calculate the 3-year survival rates in 93
and the 5-year survival in 79 patients. Both OS and DSS
were analyzed. The three-year survival data were available
for 93 patients. Thirty-Wve deaths, including 28 from laryn-
geal cancer and 7 from unrelated causes, occurred in the
study population at 3 years of follow-up. Thirty-eight
deaths, including 23 from laryngeal cancer and 15 from
unrelated cases, occurred in the study population at 5 years
of follow-up.
From the whole group of 93 patients with LSCC, 58
(62.4%) were alive at last follow-up 3 years after initial
treatment for OS and 58 (67.4%) of 86 for DSS. The diVer-
ence in the 3-year survival rates between the groups of
HPV positive versus HPV-negative patients was not signiW-
cant for OS (P = 0, 4) and DSS (P =0 . 7 7 ) .
In 26 patients from the whole group of 93 patients there
was recurrence of local or regional nodes or local plus
regional nodes. From the 33 HPV-positive patients, 11
(33.3%) developed a local or regional nodes or local plus
regional node recurrence. There was no signiWcant correla-
tion between the presence of HPV and recurrence rates at
3 years of follow up (2 =0 . 7 3 ;   P = 0.39).
From the 28 HPV-positive patients, 13 (46.4%) patients
were alive at the last 5 years of follow-up and 15 (53.6%)
patients died for OS. From the 24 HPV positive patients, 13
(54.2%) patients were alive for DSS. From the whole group
of 79 patients with LSCC 41 (51.9%) were alive at the last
5 years of follow-up after initial treatment for OS and 41
(58.6%) of 70 patients for DSS. The diVerence in the 5-year
survival rates between the groups of HPV positive and
HPV-negative patients was not signiWcant for OS
(P = 0.66) nor for DSS (0.49).
In 27 patients from the whole group of 79 patients local
or regional node recurrence or local plus regional node
recurrence was observed at the 5-year follow-up. From the
28 HPV-positive patients, 11 (39.3%) patients developed a
local or regional node recurrence or local plus regional
node recurrence. There was no signiWcant correlation
between the presence of HPV and recurrence rates at the 5-
years follow up (2 =0 . 5 ;   P =0 . 4 8 ) .
From the whole group of 49 patients with LSCC and
normal mucosa assay, 33 (67.3%) were alive at the last fol-
low-up of 3 years after initial treatment for OS. The diVer-
ence in the 3-year survival rates between the groups of
HPV positive and HPV-negative patients was not signiW-
cant (P = 0.83). In 15 patients from the whole group of 49
patients local or regional nodes or local plus regional node
recurrence was observed. From the four HPV-positive
patients, two (50%) developed a local recurrence. There
was no signiWcant diVerence between the HPV presence
and recurrence at the 3-year follow-up (2 =0 . 1 ;   P =0 . 7 6 ) .
From the group of 36 patients with normal mucosa sam-
ples 18 (50%) were alive at the last follow-up 5 years after
the initial treatment for OS. The diVerence in the 5-year
survival rates between the groups of HPV positive and
HPV-negative patients was not signiWcant (P =0 . 6 ) .  F r o m
the three patients with HPV-positive mucosa sample, two
patients developed local recurrence. There was no signiW-
cant diVerence between the HPV presence and recurrence
at 5 years of follow-up (2 =0 . 1 7 ;   P = 0.68). The statistical
analysis of the presence of HPV in squamous cell carci-
noma tumors and normal mucosa was not performed
because between the HPV presence and recurrence at the 3-
year follow-up the group of HPV-positive mucosa speci-
mens was too small for reliable evaluation.
A multivariate analysis of survival applying the Cox
regression model showed that the HPV presence in tumor
samples or normal mucosa is not an independent prognostic
factor.
Discussion
Recently, several techniques have been used to detect the
presence of HPV in tissues, for example Southern-blot
analysis, previously considered to be the most sensitive
assay or in situ hybridization analysis, which can be per-
formed on paraYn-embedded sections. Those techniques
have the disadvantage of requiring a sizable quantity of
nucleic acids and take several days to perform. PCR is
more sensitive than other techniques but its high sensitivity
may lead to product carryover or DNA contamination,
which can create problems in diagnostic applications.
DNA ampliWcation methods, such as the PCR, permit
more sensitive detection of viral DNA. Except type-speciWc
PCR primers for individual HPV genotypes, several univer-
sal PCR primer sets have been developed, including My11/
My09, OB/II, CPI/CPII, and GP5+/6+. However, it has
been shown that none of these general primer sets permits
adequate detection of the still expanding spectrum of HPV
genotypes. The sensitivity of these universal primer sets is
limited and their use will underestimate the true prevalence
of HPV. The SPF10 PCR/DEIA method was developed as a
set of HPV PCR primers for the highly sensitive detection
of all known mucosal HPV types.
Kleter et al. [8] showed that the detection rate in 83.7%
was signiWcantly higher using the SPF system as compared
with the universal primer set GP5+/6+. Kleter et al. [8] also
reported that the SPF assay detected HPV DNA in 100% of
184 formalin-Wxed, paraYn-embedded cervical carcinoma
specimens. Kleter et al. [8] reported that the novel SPF system
permitted universal and highly sensitive detection of HPV
DNA in diverse clinical materials and may improve the
molecular diagnosis and epidemiology of this important virus.S94 Eur Arch Otorhinolaryngol (2008) 265 (Suppl 1):S89–S96
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A novel, high sensitive and broad-spectrum SPF10 PCR/
DEIA method has been established and investigated in the
cervical squamous cell carcinoma [8,  9]; however, it is
poorly investigated in laryngeal cancer. The reported fre-
quency of HPV DNA in LSCC varies between 3 and 60%,
depending on tumor site, type of specimens and methods
applied for analysis, as well as the number of cases
included [2, 3, 10–12]. Some authors claim that HPV infec-
tion plays a possible role in the etiology of LSCC [2, 3, 11,
12] others do not prove this correlation [10].
To our knowledge, this is the Wrst report that has applied
SPF10 PCR primer set and PCR/DEIA and genotypes in a
big group with LSCC. HPV DNA was determined in 35.5%
of 93 paraYn-embedded tissue samples of LSCC. Koskinen
et al. [13], analyzed the incidence of HPV DNA presence
and genotypes using SPF10 PCR screening with a general
probe hybridization and INNO-LiPA HPV genotyping
assay in head and neck squamous cell carcinoma. Thirty-
seven of 61 (61%) samples were HPV positive. HPV-16
was the most frequently detected type and it was present in
31 of 37 HPV positive samples. They detected multiple
type infections in 8 of 37 (22%) of the HPV-positive sam-
ples and co-infection by HPV-16 and HPV-33 was predom-
inant [13]. In the group analyzed by Koskinen et al. [13],
the material was obtained from variety of primary tumors.
They included hypopharynx, larynx, tongue, oral cavity and
tonsil carcinoma samples. The incidence of HPV infection
was higher in patients with tonsil and oral cavity carci-
noma. Pirog et al. [14] using the SPF 10 primer set and line
probe assay (LiPA) method demonstrated the presence of
HPV DNA in 82 of 90 (91%) patients with mucinous ade-
nocarcinomas, and in all 9 adenosquamous tumors (100%).
The most common viral types detected in adenocarcinoma
were HPV16 (50%) and HPV 18 (40%), followed by HPV
45 (10%), HPV 52 (2%), and HPV 35 (1%). Multiple HPV
types were detected in 9.7% of the cases. Almadori et al.
[15] using PCR technique with HPV consensus primers,
detected HPV DNA in 15 of the 42 (35.7%) tumors, and it
belonged almost exclusively to the highly oncogenic HPV-
16, HPV-18, and HPV-33 genotypes. In 1996, Almadori
et al. [16] detected HPV DNA in 9 of 45 (20%) patients
using PCR technique. They also showed that in 55% of the
patients, the HPV-positive tumors were G2 and in 33% G3.
Fifty-Wve percent of the HPV positive had no clinical cervi-
cal lymph nodes (N0). It was observed that 78% of the
HPV positive cancer patients were T3–T4. Almadori et al.
[16] described more HPV-positive patients with supraglot-
tic tumors than with tumors in other locations. Hoshikawa
et al. [17] detected HPV DNA in 17.6% of laryngeal cancer
patients by PCR. Glottic laryngeal carcinoma was HPV
positive in 44.4% cases and it was signiWcantly higher than
8.7% HPV positive supraglottic tumors. They suggested
that HPV infection might be more frequent in the vocal
cord tumors than in other laryngeal sites. The data also
showed that HPV-16 was the most frequently detected type
and it was present in 27 of 33 HPV-positive samples and
multiple type infections were detected in 5 of 33 (15.1%) of
the HPV-positive samples. The results support the role of
high-risk types of HPV in LSCC.
The data in the present study showed that the HPV-posi-
tive tumors were more frequently located in supraglottis
than in glottic region, but patients with supraglottic tumors
were the majority of the whole group and statistical analy-
sis revealed no signiWcant diVerences in the incidence of
HPV and localization of the tumor.
Some authors claim that HPV DNA is more frequently
detected in well diVerentiated [18,  19], than in poorly
diVerentiated squamous cell carcinoma of the upper aero-
digastive tract [20]. In this study, HPV was detected more
often in well diVerentiated (63.3%) and moderately (20%)
diVerentiated than in poorly (16.7%) diVerentiated
tumors. Still, the diVerences were not statistically signiW-
cant. Gillison et al. [21] demonstrated that HPV-positive
head and neck squamous cell carcinomas (HNSCCs) were
not statistically signiWcantly diVerent from HPV-negative
HNSCCs with regard to the well-established risk factors
of alcohol consumption and tobacco exposure. Similar
results were obtained in this study. Gillison et al. [21]
found that HPV-positive HNSCC patients had signiW-
cantly improved DSS when compared with HPV-negative
tumors, even after adjustment for age, lymph node status,
and heavy alcohol consumption. The improved DSS sur-
vival in patients with HPV-positive HNSCC reported by
Gillison et al. [21] is somewhat surprising and remains
unexplained.
In the present study HPV-positive LSCC patients had no
signiWcantly improved OS and DSS survival when com-
pared with patients with HPV-negative tumors. Gillison
et al. [21] suggested that patients with HPV-positive tumors
might be less susceptible to the development of synchro-
nous or metasynchronous tumors in the lungs, esophagus,
and elsewhere in the head and neck that could adversely
aVect the long-term survival. The HPV-positive tumors
may be less associated with alcohol and tobacco exposure
and HPV infections tend to be focal, Wled cancerization in
which the upper respiratory epithelium is repeatedly
exposed to carcinogens my be less applicable [22].
In the present study HPV DNA infection in normal
laryngeal mucosa from the surgical margin in patients with
LSCC was detected in 8.2% of 49 normal mucosa samples
but none of the samples from control group was HPV DNA
positive. A prevalence of 4% of HPV DNA infection in
normal laryngeal mucosa of healthy patients has been
reported by Brandsma et al. [23]. Nunez et al. [24] deter-
mined the prevalence of HPV in a series of normal laryn-
geal mucosa. Twelve autopsy larynges were collected.Eur Arch Otorhinolaryngol (2008) 265 (Suppl 1):S89–S96 S95
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Evidence of HPV infection was documented by the PCR
using oligonucleotide primers complementary to sequences
in the E6 region of HPV types 11, 16 and 18. HPV type 11
was isolated from three specimens. A 25% prevalence rate
for HPV 11 was found. No other HPV types were isolated
[24]. The presence of HPV infection in the premalignant
and hyperplastic laryngeal lesions is controversial. Poljak
et al. [25] analyzed the prevalence of HPV in laryngeal epi-
thelial hyperplastic lesions using PCR and in situ hybridiza-
tion methods. HPV was present in only 2 of 88 specimens
and the authors suggested that most of hyperplastic lesions
in the larynx are not associated with HPV infection.
Conclusion
The presence of HPV infection in 35.5% of the cases sug-
gests a possible role in the etiology of laryngeal cancer and
supports the role of high-risk types of HPV (16, 18 and 33)
in LSCC. The incidence of HPV infection in patients with
LSCC tumor was signiWcantly higher than in control group
and higher than in normal mucosa from the surgical margin
in patients with LSCC samples.
HPV infection is not likely to inXuence survival rates as
an independent prognostic factor in patients with laryngeal
cancer. The high sensitive and speciWc SPF10 HPV DNA
test, PCR/DEIA method and INNO-LiPA genotyping assay
can be performed for HPV detection on paraYn-embedded
sections collected during diagnostic procedures as good
screening test.
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